Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Key Highlights
- ➤BLTE data to be presented at Innovate Retina and AAO 2026 in New Orleans
- ➤AAO presentation features topline 24-month Phase 3 DRAGON results
- ➤FDA accepted tinlarebant NDA with priority review in August 2026
- ➤FDA set February 12, 2027, Prescription Drug User Fee Act date
Expert Statements
Paul Bernstein, Professor of Ophthalmology and Vice-Chair for Clinical and Basic Science Research at the Moran Eye Center, University of Utah
“What Is Coming to the Clinics: Tinlarebant for Stargardt Disease”
Quan Dong Nguyen, Professor of Ophthalmology at the Byers Eye Institute and Professor of Pediatrics and Professor of Medicine (Immunology and Rheumatology), Stanford University School of Medicine
“Topline 24-Month Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt Disease”
Jacque L. Duncan, Department Chair and Professor of Ophthalmology, University of California, San Francisco School of Medicine
“Phase 3 DRAGON Trial of Tinlarebant for Stargardt Disease (STGD1)”
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio(®)” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Innovate Retina conference being held on October 8, 2026, in New Orleans, Louisiana, and at the American Academy of Ophthalmology (AAO) 2026 being held on October 9-12, 2026, in New Orleans, Louisiana.
Session 1: Inherited Retinal Diseases (IRD) Title: What Is Coming to the Clinics: Tinlarebant for Stargardt Disease Presenter: Paul Bernstein, MD, PhD, Professor of Ophthalmology and Vice-Chair for Clinical and Basic Science Research at the Moran Eye Center, University of Utah Date and Time: October 8, 2026 3:04 – 3:07 p.m. CST Location: InterContinental New Orleans, Salle A-C Ballroom (3rd floor)
Get started
Create a free account to read the full story.